Sixteen patients with generalized granuloma anulare and two patients with localized granuloma anulare received bath-PUVA therapy. Their lesions previously had not responded to conventional therapy. After an average of 55 (11 to 61) treatments and a mean cumulative dose of 69.5 (7.1 to 261.5) J/cm2, complete remission was observed in 5 patients and a clear improvement in 10 patients. Three patients stopped therapy after few treatments. Recurrent lesions appeared in 4 patients; in three of them reinitiation of the bath-PUVA-therapy again led to complete remission. Maintenance therapy for several months may be useful for patients suffering from relapsing granuloma anulare. Potential risks of long-lasting bath-PUVA therapy should be taken into consideration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s001050050901 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical variables and management of disseminated granuloma annulare - monocentric retrospective analysis of 33 cases between 2021 and 2023].
Dermatologie (Heidelb)
January 2025
Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland.
Article Synopsis
- Granuloma annulare (GA) is a non-infectious skin condition that can become widespread in some patients; this study focused on those with disseminated GA in a German hospital.
- A total of 239 patients were studied, with 33 having confirmed disseminated GA, predominantly affecting women around the age of 57, and many reporting little to no symptoms.
- Treatment options included glucocorticoids and phototherapy, but only a small percentage achieved remission, highlighting the need for more effective clinical trials for new therapies.
Clinical Manifestations of European Borreliosis on the Skin in Acute, Subacute and Chronic Disease.
Mater Sociomed
January 2024
Department of Biosciences, COMSATS University Islamabad (CUI), Park Road, Chakh Shahzad, Islamabad, Pakistan.
Article Synopsis
- Lyme borreliosis, caused by the Borrelia burgdorferi spirochete, is a complex infection primarily indicated by erythema migrans on the skin.
- A study examining 509 patients over nine years aimed to explore skin manifestations and their impact on diagnosis and treatment, revealing various clinical presentations beyond just erythema migrans.
- Findings showed that while erythema migrans is a key marker, other skin conditions like "pink borreliosis stretch marks" and "borreliosis palms or soles" are important for diagnosing chronic borreliosis.
Oral abrocitinib in the treatment of granuloma annulare: a case report.
J Dermatolog Treat
December 2024
Institute of Dermatology, Guangzhou Medical University, Guangzhou, P.R. China.
To evaluate the therapeutic efficacy and safety of JAK inhibitor abrocitinib in patients with localized granuloma annulare (GA) and to review the available cases documented in English. We presented a patient who had a persistent, localized granuloma anulare (GA) for one year and did not respond to traditional therapies. This patient was treated with oral abrocitinib at a dosage of 150 mg daily.
View Article and Find Full Text PDFGranuloma Annulare: A Rare and Unusual Lesion of the Eyelid.
Klin Monbl Augenheilkd
October 2023
Department of Pathology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
[Not Available].
J Dtsch Dermatol Ges
June 2021
Klinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum des Saarlandes, Homburg/Saar.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!